2026 · 2nd Quarter (Apr 1 - June 30)

BRAEBURN PHARMACEUTICALS, INC.

Filed by STANTON PARK GROUP.

Open official filing

Source-reported fields

Filing overview

Type: 2nd Quarter - Report
Posted: Jul 20, 2026
Income: $50,000.00
Expenses: Not reported
Registrant: STANTON PARK GROUP
Client: BRAEBURN PHARMACEUTICALS, INC.
Filing UUID: dee12b13-609c-4da9-b4b8-059eb8d22909
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

Reducing stigma and promoting treatment of opioid use disorder; raising awareness of the benefits of medication assisted therapy (MAT); ensuring patient access to MAT; FDA approval and exclusivity process; Patient access to practitioner-administered therapies; MAT availability in federal prisons

MMM · Medicare/Medicaid

Pilot programs related to Medicaid pricing

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.